Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Gamma hydroxybutyrate (GHB) intoxication

Deborah L Zvosec, PhD
Stephen W Smith, MD
Section Editors
Stephen J Traub, MD
Michele M Burns, MD, MPH
Deputy Editor
Jonathan Grayzel, MD, FAAEM


Gamma hydroxybutyrate (GHB) is a central nervous system (CNS) depressant first synthesized in France as an analog of gamma aminobutyric acid (GABA) and capable of crossing the blood brain barrier. Initially used as an anesthetic in Europe, GHB's inadequate analgesic effects and side effects, including myoclonus and emergence delirium, prevented approval in the United States (US) [1].

In the 1980s GHB was marketed as a bodybuilding and weight loss drug and sold in health food stores. Subsequently, use became more widespread as GHB was abused for euphoric, sexual, stimulant, and relaxant effects. Following reports of adverse effects and the enactment of government restrictions on GHB, the marketing of gamma butyrolactone (GBL) and 1,4 butanediol (BD), two common industrial solvents, as “dietary supplements” began. Both of these compounds are analogs or congeners of GHB, which when ingested are rapidly metabolized to GHB, with the same clinical effects. (See 'Pharmacology and cellular toxicology' below.)

GBL and BD have been sold spuriously as “non-toxic” and “organic” solvents, “cleaning products,” and “chemical samples” to avoid detection and prosecution [2]. Available formulations include industrial GBL and BD, street supplies, home-synthesized GHB (made from recipes available on the Internet), and pharmaceutical formulations. Internet websites, chat rooms, and forums have figured prominently in the dissemination of information and misinformation regarding GHB sources and supplies, use and effects, and legal status around the world [3-5]. (See 'Formulations and dosing' below.)

The toxicology and management of acute GHB intoxication are reviewed here. GHB withdrawal, the toxicology of other specific agents that may be coingested, and general management of the poisoned patient are discussed elsewhere. (See "Gamma hydroxybutyrate (GHB) dependence and withdrawal" and "MDMA (ecstasy) intoxication" and "Cocaine: Acute intoxication" and "General approach to drug poisoning in adults".)

Throughout this review we use the term "GHB" to refer to GHB and its analogs, unless specifically noted. The pharmacology of GHB and its analogs are discussed in the text. (See 'Pharmacology and cellular toxicology' below.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jan 2017. | This topic last updated: Tue Aug 07 00:00:00 GMT+00:00 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Dyer JE. gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9:321.
  2. Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87.
  3. Boyer EW, Shannon M, Hibberd PL. Web sites with misinformation about illicit drugs. N Engl J Med 2001; 345:469.
  4. Wax PM. Just a click away: recreational drug Web sites on the Internet. Pediatrics 2002; 109:e96.
  5. Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs 2007; 39:115.
  6. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings 2010. Ann Arbor, MI: National Institute on Drug Abuse, National Institutes of Health, 2011:58.
  7. Drug Abuse Warning Network (DAWN). The DAWN Report: Trends in drug-related Emergency Department visits, 1994-2002 At a Glance. Rockville, MD: U.S. Department of Health and Human Services SAMHSA, Office of Applied Studies, 2003.
  8. Drug Abuse Warning Network (DAWN). Drug Abuse Warning Network, 2007: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2010.
  9. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391.
  10. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.
  11. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010; 48:979.
  12. Editorial team. The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 2010; 15.
  13. Hillebrand J, Olszewski D, Roumen S. GHB and its precursor GBL: an emerging trend case study. EMCDDA. Lisbon, 2008.
  14. Miró O, Nogué S, Espinosa G, et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40:129.
  15. Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134:534.
  16. Liechti ME, Kunz I, Greminger P, et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81:323.
  17. Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39:234.
  18. Elliott SP. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26:432.
  19. Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998; 91:56.
  20. Dillon, P, Degenhardt, L. Ketamine and GHB: New trends in club drug use? J Subst Use 2001; 6:11.
  21. Galicia M, Nogué S, To-Figueras J, et al. [Poisoning by liquid ecstasy (GHB) in hospital emergency departments of Barcelona: a 2-years study]. Med Clin (Barc) 2008; 130:254.
  22. Hovda KE, Bjornaas MA, Skog K, et al. Acute poisonings treated in hospitals in Oslo: a one-year prospective study (I): pattern of poisoning. Clin Toxicol (Phila) 2008; 46:35.
  23. Degenhardt L, Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy 2008; 19:311.
  24. Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20:521.
  25. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188:709.
  26. Wood DM, Warren-Gash C, Ashraf T, et al. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 2008; 101:23.
  27. Sumnall HR, Woolfall K, Edwards S, et al. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92:286.
  28. Stein LA, Lebeau R, Clair M, et al. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 2011; 20:30.
  29. Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5:365.
  30. Akins BE, Miranda E, Lacy JM, Logan BK. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009; 54:495.
  31. Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004; 28:481.
  32. Couper FJ, Logan BK. GHB and driving impairment. J Forensic Sci 2001; 46:919.
  33. Dresen S, Kempf J, Weinmann W. Prevalence of gamma-hydroxybutyrate (GHB) in serum samples of amphetamine, metamphetamine and ecstasy impaired drivers. Forensic Sci Int 2007; 173:112.
  34. Oestreich A, Iten PX. First cases of driving under the influence of Gamma hydroxybutyric acid (GHB) in Switzerland. 39th Annual Meeting of the International Association of Forensic Toxicologists (TIAFT). Prague, August 30th, 2001.
  35. Caldicott DG, Edwards N. Traumatic brain injury after a motor vehicle accident: fact or "fantasy"? Emerg Med J 2001; 18:458.
  36. Vevelstad M. Gamma-hydroxybutyrate (GHB), pregabalin and driving impairment. ICADTS 2010.
  37. Al-Samarraie MS, Karinen R, Mørland J, Stokke Opdal M. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010; 66:987.
  38. Jones AW, Holmgren A, Kugelberg FC. Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 2007; 31:566.
  39. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci Med Pathol 2008; 4:205.
  40. Piastra M, Barbaro R, Chiaretti A, et al. Pulmonary oedema caused by "liquid ecstasy" ingestion. Arch Dis Child 2002; 86:302.
  41. Savage T, Khan A, Loftus BG. Acetone-free nail polish remover pads: toxicity in a 9-month old. Arch Dis Child 2007; 92:371.
  42. Dyer, JE, Haller, CA. Gamma hydroxybutyrate and the comatose patient. Pulmonary and Critical Care Update, Chest Online 2001, Lesson 22. Available online at: www.chestnet.org/education/online/pccu/vol14/index.php (Accessed on August 22, 2007).
  43. Fieguth A, Albrecht K, Weller JP, et al. [First report of lethal gamma-hydroxybutyrate (GHB) intoxication after consumption of gamma-butyrolactone (GBL) in Lower Saxony]. Arch Kriminol 2009; 223:45.
  44. Zvosec DL, Smith SW, Porrata T, et al. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29:319.
  45. Runnacles JL, Stroobant J. [gamma ]-Hydroxybutyrate poisoning: Poisoning from toy beads. BMJ 2008; 336:110.
  46. Gunja N, Doyle E, Carpenter K, et al. Gamma-hydroxybutyrate poisoning from toy beads. Med J Aust 2008; 188:54.
  47. Suchard J, Nizkorodov S, Wilkinson S. 1,4-Butanediol content of aqua dots children's craft toy beads. J Med Toxicol 2009; 5:120.
  48. Stillwell ME. Drug-facilitated sexual assault involving gamma-hydroxybutyric acid. J Forensic Sci 2002; 47:1133.
  49. Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2005; 12:175.
  50. Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010; 24:1281.
  51. Marinetti L, LeBeau M. The use of GHB and analogs to facilitate sexual assault. For Sci Rev 2010; 22:41.
  52. Carter LP. Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault. Drug Test Anal 2011; 3:586.
  53. Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int J Legal Med 2010; 124:1.
  54. Caldicott DG, Chow FY, Burns BJ, et al. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004; 181:310.
  55. Zvosec DL, Smith SW. Commenting on"a review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia," by Kantrowitzet al. Clin Ther 2010; 32:780.
  56. Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002; 67:89.
  57. Wang YG. Xyrem (sodium oxybate) postmarketing adverse event reporting system. Sleep Med 2010; 11:595; author reply 595.
  58. Doherty JD, Hattox SE, Snead OC, Roth RH. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 1978; 207:130.
  60. Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006; 6:44.
  61. Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev 1994; 18:291.
  62. Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721.
  63. Kohrs FP, Porter WH. gamma-Hydroxybutyrate intoxication and overdose. Ann Emerg Med 1999; 33:475.
  64. Lettieri J, Fung HL. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 1978; 22:107.
  65. Roth RH, Delgado JM, Giarman NJ. Gamma-butyrolactone and gamma-hydroxybutyric acid. II. The pharmacologically active form. Int J Neuropharmacol 1966; 5:421.
  66. Carai MA, Colombo G, Reali R, et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 2002; 441:157.
  67. Poldrugo F, Snead OC 3rd. 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions. Neuropharmacology 1984; 23:109.
  68. Poldrugo F, Snead OC 3rd. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 1986; 3:367.
  69. Dyer JE, Haller CA. Gamma hydroxybutrate, gamma butyrolactone, and 1,4 butanediol. In: Medical Toxicology, Dart RC. (Ed), Lippincott, Williams, & Wilkins, New York 2004. p.1096.
  70. Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232.
  71. Couper, FJ, Marinetti, LJ. Gamma hydroxybutyrate: effects on human performance and behavior. Forensic Sci Rev 2002; 14:101.
  72. Zvosec, DL, Smith, SW. Gamma hydroxybutyrate (GHB) addiction and withdrawal. From the GHB Addiction Study (Abstract). Ann Emerg Med 2004; 44:S91.
  73. Dyer JE, Reed JH. Alkali burns from illicit manufacture of GHB (Abstract). J Tox Clin Toxicol 1997; 35:553.
  74. Wiley, J, Dick, R, Arnold, T. Hematuria from home-manufactured GHB (Abstract). J Tox Clin Toxicol 1998; 36:502.
  75. Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009; 18:675.
  76. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3:560.
  77. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490.
  78. Dargan PI, Jayachandran A, Button J, et al. A significant Xyrem® overdose managed conservatively despite high GHB concentrations [Abstract 251]. Clin Toxicol 2008; 46:636.
  79. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430.
  80. Xyrem® (sodium oxybate) oral solution. Available online at: jazzph.isat-tech.com/media/PI.pdf (Accessed on March 19, 2011).
  81. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21:507.
  82. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34:231.
  83. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353.
  84. Abanades S, Farré M, Segura M, et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit 2007; 29:64.
  85. Brenneisen R, Elsohly MA, Murphy TP, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625.
  86. Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006; 26:524.
  87. Abanades S, Farré M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci 2006; 1074:559.
  88. Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007; 81:178.
  89. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6:93.
  90. Haller C, Thai D, Jacob P 3rd, Dyer JE. GHB urine concentrations after single-dose administration in humans. J Anal Toxicol 2006; 30:360.
  91. Abanades S, Farré M, Barral D, et al. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007; 27:625.
  92. Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003; 43:59.
  93. Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9:730.
  94. Grove-White IG, Kelman GR. Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory. Br J Anaesth 1971; 43:113.
  95. Carter LP, Richards BD, Mintzer MZ, Griffiths RR. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 2006; 31:2537.
  96. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966; 20:506.
  97. Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma hydroxybutyrate in man. Can Anaesth Soc J 1966; 13:119.
  98. Van Sassenbroeck DK, De Neve N, De Paepe P, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45:533.
  99. Jenney, EH, Murphree, HB, Goldstein, L, Pfeiffer, CC. Behavioral and EEG effects of gamma-butyrolactone and gamma-hydroxybutyric acid in man. Cardiovasc Pharmacol 1962; 4:166.
  100. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31:716.
  101. Harraway, T, Stephenson, L. Gamma hydroxybutyrate: The Gold Coast Experience. Emerg Med (Australia) 1999; 11:45.
  102. Strickland RM, Felgate P, Caldicott DG. Survival of massive gamma-hydroxybutyrate/1,4-butanediol overdose. Emerg Med Australas 2005; 17:281.
  104. Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 2010; 21:332.
  105. Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 1999; 54:821.
  106. Haller, C, Thai, D, Manktelow, TC, et al. Cognitive and mood effects of GHB and ethanol in humans (Abstract). J Tox Clin Tox 2004; 42:762.
  107. Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 2009; 206:141.
  108. Dempsey DA, Meyers M, Fiorentino D, et al. Gamma-hydroxybutyrate (GHB) effects upon driving a car (abstract). Clin Pharmacol Ther 2008; 83:S75.
  109. Steel GC. Clinical application of gamma hydroxybutyric acid as a sleep cover in lumbar epidural block. Proc R Soc Med 1968; 61:825.
  110. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31.
  111. Ortega-Albás JJ, López-Bernabé R, García AL, Gómez JR. Suicidal ideation secondary to sodium oxybate. J Neuropsychiatry Clin Neurosci 2010; 22:352r.e26.
  112. Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med 2010; 11:500.
  113. George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. Sleep Med 2010; 11:38.
  114. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27:1327.
  115. Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med 1968; 61:821.
  116. Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23:316.
  117. Couper FJ, Logan BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography--mass spectrometry. J Anal Toxicol 2000; 24:1.
  118. Lora-Tamayo C, Tena T, Rodríguez A, et al. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133:256.
  119. Louagie HK, Verstraete AG, De Soete CJ, et al. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997; 35:591.
  120. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31:723.
  121. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000; 19:47.
  122. Higgins TF Jr, Borron SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996; 14:435.
  123. Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and Jolt: deadly new Internet drugs. Pediatrics 2000; 106:829.
  124. Couper FJ, Logan BK. Addicted to driving under the influence--a GHB/GBL case report. J Anal Toxicol 2004; 28:512.
  125. MacKenzie G, Draper H, Barnett G, Wakeel BA. An unconscious man with transient exposure of an accessory pathway. Eur J Emerg Med 2000; 7:295.
  126. Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use--New York and Texas, 1995-1996. MMWR Morb Mortal Wkly Rep 1997; 46:281.
  127. Ross TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995; 21:374.
  128. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156:380.
  129. Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone--Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:137.
  130. Lenz D, Rothschild MA, Kröner L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008; 30:755.
  131. Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990; 39:861.
  132. Hodges B, Everett J. Acute toxicity from home-brewed gamma hydroxybutyrate. J Am Board Fam Pract 1998; 11:154.
  133. Adornato BT, Tse V. Another health food hazard--gamma-hydroxybutyrate-induced seizures. West J Med 1992; 157:471.
  134. Stephens BG, Baselt RC. Driving under the influence of GHB? J Anal Toxicol 1994; 18:357.
  135. Sporer KA, Chin RL, Dyer JE, Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 2003; 42:3.
  136. Einspruch BC, Clark SM. Near fatality results from health food store sleeping potion. Tex Med 1992; 88:10.
  137. Arneson AH, Goetze J. Dietary supplement or dangerous drug? Two case reports of gamma-butyrolactone toxicity. J Emerg Nurs 2000; 26:425.
  138. Dribben, WH, Kirk, MA. A case of atrial fibrillation associated with GHB ingestion (Abstract). J Tox Clin Tox 2001; 39:315.
  139. Reed MJ, Clegg GR. Paroxysmal sympathetic surge associated with gamma hydroxybutyrate. Eur J Emerg Med 2006; 13:41.
  140. Knudsen, K. Intoxication with gamma-hydroxybutyric acid (GHB) is an increasing social and medical emergency in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:226.
  141. Roberts DM, Smith MW, Gopalakrishnan M, et al. Extreme γ-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011; 58:83.
  142. Ulrich S, Müller V, Keel M, Seebach JD. Sudden leg paralysis in a 26-year-old nurse. Swiss Med Wkly 2005; 135:206; author reply 206.
  143. Personne, M, Landgren, A. GHB intoxications in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:185.
  144. Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442.
  145. O'Toole JG, Kristian MR, Devereux L, Kurien R. Gamma-hydroxybutyrate dependence in a rural setting in Wales. J Subst Abuse 2009; 14:70.
  146. Zvosec DL, Smith SW. "Acute complications of Gamma hydroxybutyrate addiction (abstract). Acad Emerg Med 2005; 12:S13.
  147. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010; 14:77.
  148. Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003; 133:9.
  149. Mercer J, Shakleya D, Bell S. Applications of ion mobility spectrometry (IMS) to the analysis of gamma-hydroxybutyrate and gamma-hydroxyvalerate in toxicological matrices. J Anal Toxicol 2006; 30:539.
  150. Gottardo R, Bortolotti F, Trettene M, et al. Rapid and direct analysis of gamma-hydroxybutyric acid in urine by capillary electrophoresis-electrospray ionization ion-trap mass spectrometry. J Chromatogr A 2004; 1051:207.
  151. Bortolotti F, De Paoli G, Gottardo R, et al. Determination of gamma-hydroxybutyric acid in biological fluids by using capillary electrophoresis with indirect detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800:239.
  152. Villain M, Cirimele V, Ludes B, Kintz P. Ultra-rapid procedure to test for gamma-hydroxybutyric acid in blood and urine by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792:83.
  153. Kintz P, Villain M, Ludes B. Testing for the undetectable in drug-facilitated sexual assault using hair analyzed by tandem mass spectrometry as evidence. Ther Drug Monit 2004; 26:211.
  154. De Paoli G, Walker KM, Pounder DJ. Endogenous γ-hydroxybutyric acid concentrations in saliva determined by gas chromatography-mass spectrometry. J Anal Toxicol 2011; 35:148.
  155. Bravo DT, Harris DO, Parsons SM. Reliable, sensitive, rapid and quantitative enzyme-based assay for gamma-hydroxybutyric acid (GHB). J Forensic Sci 2004; 49:379.
  156. Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40:781.
  157. Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45:261.
  158. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147.
  159. Slagel B, Kingstone E, Bhalerao S. Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient. Can J Psychiatry 2003; 48:131.
  160. Varela M, Nogué S, Orós M, Miró O. Gamma hydroxybutirate use for sexual assault. Emerg Med J 2004; 21:255.
  161. LeBeau, M. Toxicological investigations of drug-facilitated sexual assaults. Forensic Science Communications 1999; 1:1.